Javascript seems to be disabled. This will break some core site features. Please enable javascript or revisit this site from another device.
15:10
4941-A-2326 Circulating collagen neoepitopes are associated with multi-organ disease in the ACCESS and GRADS sarcoidosis cohorts
15:15
4986-A-2326 EPIDEMIOLOGICAL EVIDENCE OF FAMILIAL AGGREGATION OF SARCOIDOSIS AND AUTOIMMUNITY
15:20
4999-A-2326 SARCOIDOSIS AND EMERGENCY HOSPITALIZATION
15:25
5060-A-2326 CIRCULATING UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR PROTEIN HIGHLY CORRELATES WITH THE SEVERITY OF IDIOPATHIC PULMONARY FIBROSIS (IPF): DATA FROM THE IPF-PRO REGISTRY
15:30
5093-A-2326 Evaluation of the Systemic Immune Inflammation Index in Sarcoidosis Patients
15:35
5098-A-2326 Incidence of Cardiac Sarcoidosis in patients with Pulmonary Sarcoidosis and no previous cardiac disease: Results from the prospective CASPA screening study in the UK
15:40
5099-A-2326 Presenting symptoms and prior cardiac investigations in the evaluation of patients with suspected Cardiac Sarcoidosis: Interim data from the multicentre PAPLAND study
15:45
5132-A-2326 THE ROLE OF AIRWAY EPITHELIAL RESPONSES IN SARCOIDOSIS
15:50
5150-A-2326 Bronchoscopy in Sarcoidosis - a singel center retrospective analysis
15:55
5162-A-2326 Inflammatory Proteins in Multiorgan Sarcoidosis
16:00
5247-A-2326 IDENTIFYING SIGNAL REGULATORY PROTEIN IN SARCOIDOSIS TISSUES: A RETROSPECTIVE ANALYSIS
16:05
5157-A-2326 Seasonal variation in Swedish sarcoidosis patients with hypercalcemia
15:05
4769-A-2326 RE-HOSPITALISATION PREDICTS POOR PROGNOSIS AFTER ACUTE EXACERBATION OF INTERSTITIAL LUNG DISEASE
15:10
4773-A-2326 Outcomes of immune and nonimmune causes of Diffuse alveolar hemorrhage
15:14
4966-A-2326 EFZO-FITTM: A PHASE 3 STUDY OF EFZOFITIMOD, A NOVEL IMMUNOMODULATOR FOR THE TREATMENT OF PULMONARY SARCOIDOSIS
15:18
4976-A-2326 INFLIXIMAB THERAPY FOR THE MANAGEMENT OF SARCOIDOSIS: A SINGLE CENTRE REAL-WORLD ANALYSIS.
15:22
4990-A-2326 IMBALANCE IN B LYMPHOCYTES SUBPOPULATION IN LYMPH NODES ASPIRATES AND PERIPHERAL BLOOD IN SARCOIDOSIS PATIENTS.
15:27
4997-A-2326 NINTEDANIB IN PROGRESSIVE PULMONARY FIBROSIS-SINGLE CENTRE EXPERIENCE
15:32
4998-A-2326 THERAPEUTIC EFFECT OF A NOVEL MMP-12 INHIBITOR IN A CARDIAC SARCOIDOSIS MOUSE MODEL
15:37
5005-A-2326 Using electronic nose technology to predict response to immunosuppressive treatment in patients with interstitial lung disease
15:41
5127-A-2326 Unveiling common molecular pathways linked to ILDs with progressive fibrosing phenotype: the role of MUC5B promoter variants
15:45
5130-A-2326 PROGNOSTIC IMPACT OF VENOUS THROMBOEMBOLISM ON THE COURSE OF SARCOIDOSIS: A MULTICENTER RETROSPECTIVE CASE-CONTROL STUDY
15:50
5137-A-2326 GRANULOMATOUS DISEASE IN SARCOIDOSIS AND COMMON VARIABLE IMMUNE DEFICIENCY: SIMILAR MECHANISM OR DIFFERENT DISEASE ENTITIES?
15:55
5200-A-2326 Tracking respiratory infections in sarcoidosis: The SARCoidosis Outcomes in (all) respiratory Viral Infectious Diseases (SARCOVID) study